Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

Summary

To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain.

Timeline

Start

2014-10-20

Primary completion

2016-05-23

Completion

2016-05-23

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Ticagrelor vs Aspirin; p = 0.3441; Mean Difference (Net) -0.1 (95% CI -0.4 to 0.1); t-test, 2 sided NCT02227368 ↗

Publications

• Rogers RK, Hiatt WR, Patel MR, Shishehbor MH, White R, Khan ND, Bhalla NP, Jones WS, Low Wang CC. Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. Vasc Med. 2018 Dec;23(6):513-522. doi: 10.1177/1358863X18760996. Epub 2018 Apr 9.

Drugs

Indications